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Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal
women with bulky hormone receptor-positive breast cancer. Recent studies indicate that tumour response in this setting may predict
long-term outcome of patients on adjuvant endocrine therapy, which argues for its broader application in treating hormone receptor-
positive disease. From the research perspective, neoadjuvant endocrine therapy provides a unique opportunity for studies of
endocrine responsiveness and the development of novel therapeutic agents.
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For patients with locally advanced breast cancer, neoadjuvant
chemotherapy is commonly recommended to improve surgical
outcomes. However, for postmenopausal women with oestrogen
receptor (ER)-positive disease, endocrine treatment is a logical
alternative because of its established efficacy in the adjuvant
setting (EBCTCG, 2005) and the increasing recognition that
chemotherapy may be less effective in ERþ HER2  disease
(Berry et al, 2006; Hayes et al, 2007). Historically, neoadjuvant
endocrine therapy was reserved for older and frail patients with
ERþ breast cancer. However, recent studies of this treatment
modality in younger and healthier postmenopausal women showed
that the improved surgical outcomes and response observed with
the endocrine approach do not show an interaction with age
(Olson et al, 2009), justifying the increased acceptance of
neoadjuvant endocrine therapy in younger postmenopausal
women with better performance status. For premenopausal
women, neoadjuvant endocrine therapy remains investigational.
In this review, we will present results of the major neoadjuvant
aromatase inhibitor (AI) trials and discuss recent progress in using
neoadjuvant endocrine therapy as a research tool to assess
endocrine responsiveness and evaluate novel therapeutic inter-
ventions.
NEOADJUVANT ENDOCRINE THERAPY:
THE CLINICAL DATA
The potential benefit of endocrine therapy in the neoadjuvant
setting was initially suggested in earlier studies of tamoxifen, as a
primary treatment approach for elderly women with breast cancer
who were too frail to undergo other forms of therapy such as surgery
(Preece et al, 1982; Horobin et al, 1991; Bergman et al, 1995).
The clinical response rate was in the range of 30% and higher, with
long-lasting responses observed in some of these patients (Preece
et al, 1982; Bergman et al, 1995). Subsequent randomised trials of
tamoxifen vs surgery followed by tamoxifen conducted in elderly
women with operable breast cancer showed that surgery is essential
for optimal local control, but tamoxifen alone achieved a similar
overall survival compared with surgery followed by tamoxifen
(Willsher et al, 1997; Mustacchi et al, 2003; Hind et al,2 0 0 6 ;
Chakrabarti et al, 2010). These investigations laid the foundation for
the design of subsequent studies of AIs in younger and healthier
postmenopausal women with bulky hormone receptor (HR)-positive
disease to achieve better surgery outcome. The letrozole P024 trial
(Eiermann et al, 2001), the Immediate Preoperative Anastrozole,
Tamoxifen or Combined with Tamoxifen (IMPACT) trial (Smith
et al, 2005) and the Preoperative ‘Arimidex’ Compared to Tamoxifen
(PROACT) trial (Cataliotti et al, 2006) were three of these studies
(Table 1).
In the P024 trial, letrozole treatment was associated with a
statistically significant improvement in the rate of breast
conservation compared with tamoxifen. The anastrozole-based
IMPACT and PROACT trials also showed a trend favouring the AI
arm, although the results in comparison with tamoxifen were not
statistically significant (Smith et al, 2005; Cataliotti et al, 2006).
A meta-analysis of these trials supported the notion that an AI was
more effective than tamoxifen for promoting breast conservation
(Seo et al, 2009). A promising 76% rate of breast conservation was
also observed in a single arm phase II study of neoadjuvant
exemestane in postmenopausal patients with HRþ tumours 3cm
or greater after 12 weeks of therapy (Mlineritsch et al, 2008). The
American College of Surgeons Oncology Group has recently
completed accrual to the randomised phase III Z1031 trial to
determine whether there are any differences in efficacy between
the three approved AIs in this setting (NCT00698971). Preliminary
data from this trial indicate that there are no clinically significant
differences between these agents as neoadjuvant treatment
(Ellis et al, 2010).
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In an early study by Gazet et al (2001), 13 premenopausal women
with ERþ breast cancer received neoadjuvant goserelin, a
gonadotropin-releasing hormone (GnRH) analogue. At 3 months,
seven of the 13 women had an overall response by clinical
assessment, suggesting that premenopausal women may also
benefit from neoadjuvant endocrine manipulation (Gazet et al,
2001). Torrisi et al (2007) investigated the use of letrozole and a
GnRH analogue as primary therapy in premenopausal women with
ERþ breast cancer. These patients received a GnRH analogue for
a median of 5.2 months and letrozole for a median of 4 months. In
the 32 evaluable patients, one achieved a pathological complete
response (pCR) and 15 obtained a clinical and imaging partial
response (Torrisi et al, 2007). These studies suggest that
neoadjuvant endocrine therapy is effective in selected premeno-
pausal women with ERþ breast cancer and further study in this
patient population is needed.
COMPARISON WITH PREOPERATIVE
CHEMOTHERAPY
A direct comparison between neoadjuvant chemotherapy and
endocrine therapy was reported by Semiglazov et al (2007), in
which 239 postmenopausal women with untreated invasive breast
cancers that were ER and/or progesterone (PgR) positive received
either combination chemotherapy with doxorubicin and paclitaxel
every 3 weeks for four cycles (n¼118) or AI treatment with
either exemestane (n¼60) or anastrozole (n¼61) for 3 months
(Semiglazov et al, 2007). The clinical overall response, rates of pCR
and disease progression did not differ significantly among the
groups. The breast conservation rate was slightly higher in the
AI groups at 33% compared with 24% in the chemotherapy arm.
These findings support the hypothesis that AI therapy is an
appropriate low toxicity neoadjuvant approach, but a definitive
randomised study that compares neoadjuvant endocrine therapy
to chemotherapy has yet to be reported. Ideally, a trial that
compares the two approaches would take a predictive model
forward into the clinical trial design, as subpopulations of breast
cancer may benefit more from chemotherapy, while others from
endocrine manipulation (van de Vijver et al, 2002; Paik et al, 2004;
Parker et al, 2009).
More recently, the GEICAM cooperative group reported a
randomised phase II trial of chemotherapy vs exemestane in
pre- and postmenopausal women (Alba et al,2 0 1 0 ) .N i n e t y - f i v e
patients with localised ERþ,P g R þ,H E R 2   and CK8/18þ
(immunohistochemistry marker for luminal subtype) breast cancer
were randomly assigned to chemotherapy (epirubicin plus cyclo-
phosphamide every 3 weeks for four cycles followed by docetaxel
every 3 weeks for four cycles) (n¼47) or exemestane (with
goserelin if premenopausal) (n¼48). Tumour response was
measured by magnetic resonance imaging. More than 50% of the
participants were premenopausal women (n¼24 in the chemo-
therapy arm and n¼27 in the hormonal therapy arm). The
response rate was higher for chemotherapy in the premenopausal
patients (18 of the 24 in the chemotherapy arm vs 12 of the 27 in the
hormonal therapy arm, P¼0.027), but in postmenopausal women
and those with a low baseline Ki67, responses were comparable. The
underperformance of exemestane and goserelin in premenopausal
women may reflect the fact that this can be inadequate for endocrine
therapy in some patients, with a failure to suppress ovarian
function. Alternatively, primary endocrine therapy resistance is
likely to be higher in a premenopausal population and a more
accurate predictive model for endocrine therapy efficacy is needed.
RECEPTOR STATUS AS SELECTION CRITERIA FOR
NEOADJUVANT ENDOCRINE THERAPY
Oestrogen receptor positivity remains the single most important
criterion for eligibility for neoadjuvant endocrine therapy. Patients
with an ER Allred score of 6 and above are the most likely to
respond (Ellis et al, 2001). The data on PgR status does not support
its use as a selection criterion in the context of ER positivity, and
PgRþ ER  tumours are too uncommon to make a definitive
statement with regard to their management (Ellis et al, 2001).
HER2 status has been investigated in both the IMPACT and the
P024 studies. Although the presence of HER2 amplification does not
preclude a meaningful response to an AI in the neoadjuvant setting
(Ellis et al, 2001; Smith et al, 2005), HER2 positivity is associated
with a lower suppression of Ki67, a marker of cell proliferation,
in response to either tamoxifen or letrozole (Ellis et al, 2006),
Table 1 Summary of the letrozole P024, IMPACT and PROACT trials
Letrozole P024 IMPACT PROACT
Postmenopausal women with HR+ breast cancer
337 randomised 330 randomised 451 randomised
Patient characteristics at baseline None were BCS candidates at
baseline; 14% deemed inoperable
Pretreatment surgical assessment
available for 220 patients – 96 eligible
for BCS
386 of the patients either required
a mastectomy or were deemed
inoperable at baseline
Definition of HR positivity ER/PgR staining 410% ER staining 41% ‘ER+/PgR+’
Neoadjuvant endocrine therapy L for 4 months
T for 4 months
A for 12 weeks
A+T for 12 weeks
T for 12 weeks
A for 3 months
T for 3 months
Concomitant chemotherapy? No — Yes
Primary end point Clinical response by palpation Overall response by caliper
measurements
Overall response by ultrasound
measurements
Response (per primary end point) 55% (L) vs 36% (T); Po0.001 37% (A) vs 39% (A+T) vs 36% (T) 39.5% (A) vs 35.4% (T)
Rate of down staging to BCS 45% (L) vs 35% (T); P¼0.022 44%(A) vs 24% (A+T) vs 31% (T) 43.0% (A) vs 30.8% (T) in improved
feasible surgery in hormone therapy-
only group (n¼314)
Abbreviations: A¼anastrozole 1mg daily; BCS¼breast conserving surgery; ER¼oestrogen receptor; HR¼hormone receptor; IMPACT¼Immediate Preoperative
Anastrozole, Tamoxifen or Combined with Tamoxifen; L¼letrozole 2.5mg daily; PROACT¼Preoperative ‘Arimidex’ Compared to Tamoxifen; PgR¼progesterone receptor;
T¼tamoxifen 20mg daily.
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practice, most patients with HER2þ tumours receive trastuzumab
in combination with a chemotherapy regimen because of the high
pCR rate. Although the combination of trastuzumab and an AI has
shown promising results in patients with metastatic disease (Marcom
et al, 2007; Kaufman et al, 2009), it has not been adequately tested in
the neoadjuvant setting.
PREDICTING LONG-TERM OUTCOMES AFTER
NEOADJUVANT THERAPY
Neoadjuvant chemotherapy studies have firmly established that
response, and particularly pCR, is a strong predictor of survival in
breast cancer patients. However, in the subset of patients with ERþ
HER2  disease treated with chemotherapy, pCR has limited value,
as these patients often do well despite the absence of pCR because
of effective adjuvant endocrine therapy (Buchholz et al, 2001).
Pathological CR is very uncommon in response to neoadjuvant
endocrine therapy. In three relatively large studies with letrozole,
the pCR rate was no more than 1% (Eiermann et al, 2001; Baselga
et al, 2009; Olson et al, 2009). Although residual cancer burden
after neoadjuvant chemotherapy has been shown to predict distant
relapse-free survival (Symmans et al, 2007), the application of this
measure to patients who underwent neoadjuvant endocrine therapy
remains to be evaluated. To identify alternative post-treatment
factors that predict breast cancer survival after neoadjuvant
endocrine therapy, Dowsett et al (2007) examined Ki67 expression
before and after 2 weeks of endocrine therapy. Patients with higher
Ki67 expression after 2 weeks of endocrine therapy had a
significantly lower recurrence-free survival (Dowsett et al, 2007).
In a multivariable analysis conducted on the P024 trial (Ellis et al,
2008a), four factors were determined to have independent
prognostic value for relapse and death after relapse. These included
pathological tumour size (T1/2 vs T3/4), pathological node status
(positive or negative) and two biomarkers in the surgical resection
specimen, the natural logarithm of the Ki67 value and the ER status
of the tumour. A prognostic score, the preoperative endocrine
prognostic index (PEPI), was developed, which weighs each of these
factors according to their associated hazard ratios (Table 2). The
PEPI was then validated in an independent dataset from the
IMPACT trial (Ellis et al, 2008a). No relapses were recorded in either
trial in patients with T1, N0 tumours with a PEPI score of 0 (residual
tumour with Ki67 index of 2.7% – natural logarithm of 1 – or less
with maintained ER expression) or in the rare patient with a pCR.
These patients are not likely to benefit from adjuvant chemotherapy
as endocrine therapy alone appears to adequately control their
disease. These results supported an amendment to the Z1031 trial
(Cohort B), in which chemotherapy was not recommended to
patients in the pathological stage 1/0 PEPI 0 category. The
acceptability of this advice will be assessed to see if this approach
can be made a protocol mandate in the next phase of clinical trial
development. In addition, patients with a high Ki67 proliferation
index in a 2- to 4-week biopsy (410%) are triaged to neoadjuvant
chemotherapy or immediate surgery, as these tumours are
exhibiting primary endocrine therapy resistance (Dowsett et al,
2007). To determine the chemotherapy responsiveness of this group,
the rate of pCR with neoadjuvant chemotherapy in the high on-
treatment Ki67 group will be determined (Figure 1). If this approach
to tailoring neoadjuvant endocrine therapy is feasible, a larger, more
definitive study will be considered.
GENOMICS TO DETERMINE THE MOLECULAR BASIS
FOR THE VARIABLE RESPONSE TO ENDOCRINE
THERAPY
Discovery genomics is a complex process that often requires
fresh-frozen material, an adequate sample size, patient consent to
genetic studies and access to sophisticated analysis techniques. To
date, the number of publications on genomic profiling in the context
of neoadjuvant endocrine therapy remains few and the sample sizes
are small. For example, Miller et al (2009) reported on a series of 52
patients, 37 were considered letrozole sensitive and 15 resistant. A
predictive model was developed that used all three types of gene
expression variable: baseline, on-treatment and change in treatment,
to differentiate between the two groups. This paper illustrates the
variety of bioinformatics approaches that can be taken when before
and on-treatment paired samples are available for analysis (Miller
et al, 2009). Other investigations are ongoing to assess the predictive
value of established molecular signatures, such as the Netherlands
Cancer Institute NKI 70 gene (van de Vijver et al,2 0 0 2 ) ,2 1g e n e
recurrence score (Paik et al, 2004) or the PAM50 (Parker et al,
2009), performed on tumour samples taken after the initiation of
endocrine therapy (Ellis et al, 2008b). The Z1031 trial has recently
completed accrual of 375 patients, despite mandatory fresh tumour
tissue acquisition, through the provision of tissue acquisition kits
and the active collaboration of surgical investigators. Z1031 patients
are also consented for massive parallel DNA sequencing to define
complete cancer genomes (Ding et al, 2010). Very detailed
information on the molecular characteristics of endocrine therapy-
resistant and -sensitive tumours is therefore a near-term prospect.
NEOADJUVANT TRIALS TO GENERATE
PROOF-OF-PRINCIPLE DATA FOR NOVEL
ENDOCRINE THERAPY COMBINATIONS
The superior efficacy of adjuvant aromatase inhibition vs
tamoxifen in reducing the risk of recurrence was mirrored by
Table 2 The PEPI
a
RFS BCSS
Pathology, biomarker status HR Points HR Points
Tumour size
T1/2 — 0 — 0
T3/4 2.8 3 4.4 3
Node status
Negative — 0 — 0
Positive 3.2 3 3.9 3
Ki67 level
0–2.7% (0–1
b)— 0 — 0
42.7–7.3% (1–2
b) 1.3 1 1.4 1
47.3–19.7% (2–3
b) 1.7 1 2.0 2
419.7–53.1% (3–4
b) 2.2 2 2.7 3
453.1% (44
b) 2.9 3 3.8 3
ER status, Allred score
0–2 2.8 3 7.0 3
3–8 — 0 — 0
Abbreviations: PEPI¼preoperative endocrine prognostic index; RS¼relapse-free
survival; BCSS¼breast cancer-specific survival; HR¼hazard ratio; ER¼estrogen
receptor.
aTo obtain the PEPI score, risk points for RFS and BCSS were assigned
depending on the HR defined in the P024 analysis (Ellis et al, 2008a). The total PEPI
score assigned to each patient is the sum of the risk points derived from the pT stage,
pN stage, Ki67 level and ER status of the surgical specimen. An HR in the range of
1–2 receives one risk point; an HR in the 2–2.5 range, two risk points; an HR greater
than 2.5, three risk points. The total risk point score for each patient is the sum of all
the risk points accumulated from the four factors in the model. For example, a patient
with a T1 N0 tumour, a Ki67 staining percentage of 1% and an ER Allred score of
6 will have no risk points assigned. In contrast, a patient with a T3 N1 tumour, a Ki67
staining percentage of 25% and an ER Allred score of 2 will have a total relapse score
of 3+3+2+3¼11.
bThe natural logarithm interval corresponding to the per cent Ki67
values on the original percentage scale.
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was most consistently seen with letrozole, with both the clinically
based (Eiermann et al, 2001) and Ki67-based data (Ellis et al, 2003)
correctly predicting that letrozole would be the more effective
adjuvant treatment (Thurlimann et al, 2005) several years in
advance of the actual result. Anastrozole was also shown to be a
superior antiproliferative agent in comparison with tamoxifen in
the neoadjuvant setting, and the failure of the anastrozole/
tamoxifen combination arm to improve outcomes in the ATAC
trial (Howell et al, 2005) was mirrored by the inferior anti-
proliferative response seen in the combination arm of the IMPACT
trial in comparison with anastrozole monotherapy (Dowsett et al,
2005). These datasets provide strong arguments for the value of
neoadjuvant endocrine therapy trials as a ‘proving ground’ to test
the efficacy of new endocrine therapy approaches for breast
cancer. Phase 2 randomised studies of endocrine therapy and
signal-transduction inhibitor combinations have been recently
reported for gefitinib and anastrozole (Polychronis et al, 2005;
Smith et al, 2007), and the rapamycin analogue, RAD001, with
letrozole (Baselga et al, 2009). The combination of anastrozole and
gefitinib was not found to be superior to anastrozole alone. The
combination of RAD001 and letrozole showed improved anti-
proliferative response and clinical response by palpation at the
expense of more adverse events. Perhaps, the most convincing
evidence for progress with a novel endocrine therapy combination
would be an enhanced rate of pCR as evidence for the activation of
a cell death process that would more effectively delete ERþ breast
cancer cells before the acquisition of resistance to endocrine
therapy (Crowder et al, 2009) or an increased rate of PEPI score 0
following neoadjuvant therapy.
CONCLUSIONS
Neoadjuvant AI therapy is a clinically valuable, logical and increasingly
accepted approach to neoadjuvant systemic therapy for postmeno-
pausal women with ERþ HER2  breast cancer. With an array of new
agents and predictive biomarkers to investigate, the time for further
randomised trials to compare neoadjuvant endocrine treatment with
conventional chemotherapy in a broad spectrum of patients with
ERþ breast cancer has probably passed – particularly if the trial
under consideration is not prospectively testing a predictive biomarker
for endocrine responsiveness. For future investigations, we should also
focus on the fact that for ERþ endocrine therapy-resistant disease,
conventional chemotherapy may not be adequate treatment. We
should therefore use the neoadjuvant setting to address two key issues:
the development of more effective mechanism-based treatments for
endocrine therapy-resistant disease; and the identification of ERþ
breast cancers that can be managed without chemotherapy.
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